The observation of elevated levels of the Tht-I and Tht-II cell states in breast cancer lesions after anti-PD-1 (pembrolizumab) treatment suggested that Thts responded quickly and directly to anti-PD-1 ICB. Here, PDCD1 is linked to breast carcinoma.